EP1196773A1 - Polypeptides, modulateurs et mimetiques e4orf4 et pp2a permettant d'induire une mort cellulaire selective - Google Patents

Polypeptides, modulateurs et mimetiques e4orf4 et pp2a permettant d'induire une mort cellulaire selective

Info

Publication number
EP1196773A1
EP1196773A1 EP00945500A EP00945500A EP1196773A1 EP 1196773 A1 EP1196773 A1 EP 1196773A1 EP 00945500 A EP00945500 A EP 00945500A EP 00945500 A EP00945500 A EP 00945500A EP 1196773 A1 EP1196773 A1 EP 1196773A1
Authority
EP
European Patent Office
Prior art keywords
cell
e4orf4
compound
pp2a
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP00945500A
Other languages
German (de)
English (en)
Inventor
Philip E. Branton
Richard C. Marcellus
Gordon C. Shore
Diana E. Roopchand
Joseph M. Lee
S. Serge Shahinian
A. Howard Bussey
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
McGill University
Original Assignee
McGill University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by McGill University filed Critical McGill University
Publication of EP1196773A1 publication Critical patent/EP1196773A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
    • C12Q1/025—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C12Q1/42—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving phosphatase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/03—Phosphoric monoester hydrolases (3.1.3)
    • C12Y301/03016—Phosphoprotein phosphatase (3.1.3.16), i.e. calcineurin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2510/00—Detection of programmed cell death, i.e. apoptosis

Definitions

  • the invention relates to methods for identifying pharmaceutical agents for selectively inducing cell death. Such agents are useful as therapeutics for treating conditions that involve inappropriate cell survival, such as cancer.
  • Adenoviruses normally infect differentiated epithelial cells of the upper respiratory tract in humans and. in order to replicate, force non-dividing cells into the cell cycle. In humans, the virus eventually kills the host cell.
  • Rodent cells are non-permissive for viral replication and can become transformed.
  • the viral El A proteins promote cellular proliferation and DNA synthesis by binding and inactivating cellular growth suppressors from the Rb and p300 families.
  • El A induces the cell to undergo apoptosis. This induction of apoptosis occurs via the activation of the cellular tumor suppressor. p53.
  • E4orf4 A second, p53-independent apoptotic pathway induced by E1A is mediated by the E4orf4 protein (see PCT Application No. IB97/01041. published January 15, 1998. hereby incorporated by reference.
  • E4orf4 The involvement of E4orf4 in apoptosis was indicated by our observation that adeno iruses lacking E 1B- 19K could induce apoptosis in cell lines lacking p53.
  • Using viral deletion mutants we showed that this p53- ⁇ ndependent apoptosis relied on expression of another early viral gene product, which as subsequently mapped to the E4 open reading frame 4 protein (E4orf4).
  • This apoptosis could be delayed by expressing either E 1B- 19K or cellular Bcl-2 protein, but not by E1B-55K.
  • This novel death pathway was found to be activated by adenovirus in both rodent and human cell lines, regardless of p53 expression.
  • E4orf4 has been shown to interact with PP2A, an abundant se ⁇ ne-threonine phosphatase with pleiotropic activities.
  • the holoenzyme exists in multiple forms as a heterot ⁇ mer composed of a catalytic C subunit and A and B regulatory subunits.
  • the A and C subunits, w hich make up the core enzyme are ubiquitous, each existing in two lsoforms.
  • the 65 kDa A subunit is a hook-shaped protein consisting of 15 imperfect repeats of 39 amino acids termed HEAT (huntingtin-elongation-A subumt-TOR) motifs, which are believed to mediate protein-protein interactions.
  • HEAT huntingtin-elongation-A subumt-TOR
  • the 37 kDa C subunit is able to bind to repeats 1 1- 15. while the B subunit binds to repeats 1- 10.
  • B subunits have been cloned: these have been grouped into three classes designated as B, B' and B".
  • the B class proteins are all approximately 55kDa and include at least four members.
  • Five genes ( ⁇ . ⁇ . ⁇ . ⁇ . ⁇ ) producing at least 13 splice variants make up the B' (B56) class, while the B" class contains two alternatively spliced forms of 72 kDa and 130 kDa.
  • the A and C subunits possess phosphatase activity but appear to lack substrate specificity. Specificity appears to be conferred through the va ⁇ ous B subunits.
  • Associated B subunits can either inhibit or promote phosphatase
  • E4orf4 may modulate the substrate specificity and/or subcellular localization of the B ⁇ subset of PP2A enzyme.These results seem to indicate that the E4orf4-PP2A complex is required, but not sufficient to promote cell death. Alternatively, some E4orf4 mutants may interact with B ⁇ but fail to have a biological effect on PP2A due to inexact binding.
  • PP2A of Saccharomyces (S.)cerevisiae is very similar to the mammalian enzyme with respect to organization, substrate specificity and sensitivity to inhibitors.
  • yeast the catalytic C subunit is encoded by PPH2I and PPH22.
  • the products of PPH2I and PPH22 genes share 89% amino acid sequence identity and both are at least 75% identical to the human C subunit peptide sequences.
  • Pph21 and Pph22 are unique in that, unlike PP2As of other species, they have acidic amino terminal extensions of 60 and 68 residues, respectively. These stretches share 48% identity.
  • the catalytic subunits are dispensable for cell growth when deleted individually, while strains lacking both C subunits, as well as a related gene PPH3, are inviable.
  • TPD3 encodes the only A subunit. which like the mammalian protein, contains 15 non-identical repeats of 39 residues.
  • cdc55 strains are cold sensitive and produce cells that are abnormally elongated due to defects in cytokinesis and/or septation. implicating PP2A in cell morphogenesis, rtsl strains show reduced growth at 30°C, while cells accumulate with a 2N DNA content at 37°C. Neoplastic growth, or cancer, is the unregulated growth of cells and often leads to death.
  • Surgical removal of the neoplastic cells can be ineffective because the tumor cells can invade normal, nondividing, tissue.
  • Chemotherapy another treatment, often causes severe side-effects in the patients.
  • drugs and methods for the treatment of cancer that have greater efficacy and fewer side-effects than the current treatments.
  • the invention features a method for identifying a compound as one useful for the treatment of cancer.
  • the method includes the steps of (a) providing a first cell that has been modified to have no protein phosphatase 2A biological activity and a second cell that has not been modified to have no protein phosphatase 2A biological activity; (b) contacting the cells with a candidate compound; and (c) assaying the cells for cell growth, wherein a decrease in cell growth of the second cell and no decrease in cell growth of the first cell identifies the candidate compound as a compound useful for the treatment of cancer.
  • the invention features a second method for identifying a compound as one useful for the treatment of cancer.
  • This method includes the steps of (a) providing a first cell that has been modified to have no protein phosphatase 2A biological activity and a second cell that has not been modified to have no protein phosphatase 2A biological activity; (b) contacting the cells with a candidate compound: and (c) assaying the cells for cell death, wherein an increase in cell death of the second cell and no increase in cell death of the first cell identifies the candidate compound as a compound useful for the treatment of cancer.
  • the first cell has a mutation in a gene encoding a subunit of protein phosphatase 2A that results in little or no protein phosphatase 2A biological activity.
  • a preferred subunit is a B subunit.
  • the cells are mammalian cells (e.g., human cells) or yeast cells (e.g., S. cerevisiae cells).
  • the invention features a method of increasing cell death in a cell.
  • the method includes the step of administering a compound that modulates protein phosphatase 2A (PP2A) biological activity.
  • PP2A protein phosphatase 2A
  • the PP2A biological activity is increased.
  • the PP2A biological activity is decreased.
  • the PP2A biological activity is dephosphorylation of a PP2A substrate.
  • PP2A substrates include, for example, Rb protein. Bcl-2. vimentin, casein-kinase II. and SR proteins.
  • the compound is E4orf4 mRNA, a compound that increases stability of PP2A, an E4orf4 polypeptide (e.g., one that has been modified such that it has increased biological activity relative to an E4orf4 polypeptide that has not been modified), or has at least one E4orf4 biological activity.
  • the compound is a PP2A polypeptide
  • PP2A polypeptide that has been modified such that it has increased biological activity relative to an PP2A polypeptide that has not been modified
  • has at least one PP2A biological activity e.g., a PP2A polypeptide that has been modified such that it has increased biological activity relative to an PP2A polypeptide that has not been modified
  • the invention features another method of increasing apoptosis in a cell.
  • the method includes administering to the cell an apoptosis-inducing amount of a PP2A polypeptide or cell death-inducing fragment thereof.
  • the cell is in a mammal, such as a human (e.g., a human having a cancer).
  • the invention features a method of increasing apoptosis in a mammal.
  • the method includes providing a transgene encoding a PP2A polypeptide to a cell of the mammal, the transgene being positioned for expression in the cell.
  • a preferred PP2A polypeptide includes a PP2A polypeptide that has been modified such that it has increased biological activity relative to an PP2A polypeptide that has not been modified or a PP2A polypeptide that has at least one PP2A biological activity.
  • the invention features a pharmaceutical composition that includes (i) substantially pure nucleic acid encoding a PP2A polypeptide or a cell death-inducing fragment thereof; and (ii) a pharmaceutically acceptable carrier, the composition useful for the treatment of cancer.
  • the invention features a pharmaceutical composition that includes (i) substantially pure mammalian PP2A polypeptide or a cell death-inducing fragment thereof; and (ii) a pharmaceutically acceptable carrier, the composition useful for the treatment of cancer.
  • the invention features a pharmaceutical composition that includes (i) a therapeutic amount of a compound that modulates PP2A biological activity; and (ii) a pharmaceutically acceptable carrier, the composition useful for the treatment of cancer.
  • the invention features a pharmaceutical composition that includes (i) a therapeutic amount of a compound that binds to PP2A; and (ii) a pharmaceutically acceptable carrier, the composition useful for the treatment of cancer.
  • the compound is an E4orf4 polypeptide that has been modified such that it has increased biological activity relative to an E4orf4 polypeptide that has not been modified, an agonist of E4orf4, or mimics at least one E4orf4 biological activity.
  • the invention features a method for identifying a compound useful for the treatment of cancer.
  • the method includes the steps of: (a) providing a cell expressing PP2A; (b) contacting the cell with a candidate compound; and (c) measuring binding of the compound to PP2A, wherein the binding of the compound to the PP2 A indicating a compound that is useful for the treatment of cancer.
  • the invention features another method for identifying a compound useful for the treatment of cancer.
  • the method includes the steps of: (a) providing a cell expressing PP2A; (b) contacting the cell with a candidate compound: and (c) measuring biological activity of the PP2A in the cell, wherein a change in the biological activity relative to a cell not contacted with the candidate compound indicating a compound that is useful for the treatment of cancer.
  • the cell is a mammalian cell or a yeast cell (e.g., S. cerevisiae).
  • the invention features another method for identifying a compound useful for the treatment of cancer. The method includes the steps of: (a) contacting a candidate compound with PP2A; and (b) measuring binding of the compound to PP2A, wherein a change in the binding indicating a compound that is useful for the treatment of cancer.
  • the invention features yet another method for identifying a compound useful for the treatment of cancer.
  • the method includes the steps of: (a) contacting a candidate compound with PP2A: and (b) measuring biological activity of the PP2A in the cell, wherein a change in the biological activity relative to a cell not contacted with the candidate compound indicating a compound that is useful for the treatment of cancer.
  • the invention features a method for treating a human having abnormal or excessive cell growth.
  • the method includes administering a compound that mimics or modulates PP2A biological activity.
  • the invention features another method for treating a human having abnormal or excessive cell growth, the method includes administering a compound that binds to PP2A.
  • the invention features another method for identifying a compound as one useful for the treatment of cancer.
  • the method includes: (a) providing a cell capable of expressing PP2A; (b) contacting the cell with a first compound that decreases PP2A biological activity in the cell; (c) contacting the cell with a second compound; and (d) assaying cell death of the cell, wherein a decrease in cell death relative to the cell contacted with the second compound but not the first compound identifies the second compound as a compound useful for the treatment of cancer.
  • the invention features another method for identifying a compound as one useful for the treatment of cancer.
  • This method includes: (a) providing a cell capable of expressing PP2A; (b) expressing a first compound that decreases PP2A biological activity in the cell: (c) contacting the cell with a second compound: and (d) assaying cell death of the cell, wherein a decrease in cell death relative to the cell contacted with the second compound but not expressing the first compound identifies the second compound as a compound useful for the treatment of cancer.
  • the first compound is an E4orf4 nucleic acid (e.g.. a sense or antisense E4orf4 nucleic acid that is operably linked to an inducible promoter).
  • the first compound is a PP2A A subunit that does not bind to a PP2A B subunit.
  • the cell contains nucleic acid sequence, encoding the PP2A A subunit that does not bind to a PP2A B subunit, that is operably linked to an inducible promoter.
  • the first compound is a polypeptide selected from the group of consisting of polyomavirus small T antigen, polyomavirus middle T antigen, and SV40 virus small T antigen.
  • the cell contains nucleic acid sequence, encoding polypeptide. that is operably linked to an inducible promoter.
  • the invention features still another method for identifying a compound as one useful for the treatment of cancer.
  • This method includes: (a) providing a cell that expresses an E4orf4 polypeptide that binds to a PP2A subunit but does not kill the cell; (b) contacting the cell with a compound; and (c) assaying cell death of the cell, wherein a decrease in cell death relative to a cell not expressing the E4orf4 polypeptide identifies the compound as a compound useful for the treatment of cancer.
  • the invention features another method for identifying a compound as one useful for the treatment of cancer.
  • This method includes: (a) providing a protein complex that comprises B ⁇ subunit of PP2A associated with an E4orf4 polypeptide: (b) exposing the protein complex to a candidate compound: and (c) assaying the amount of the E4orf4 polypeptide that is not associated with the B ⁇ subunit of PP2A, wherein an increase in the amount of the E4orf4 polypeptide that is not associated with the B ⁇ subunit of PP2A identifies the candidate compound as a compound useful for the treatment of cancer.
  • the protein complex is attached to a solid support.
  • the B ⁇ subunit of PP2A or the E4orf4 polypeptide is detectably labeled.
  • substantially pure protein is meant a protein of the invention that has been separated from components which naturally accompany it.
  • the protein is substantially pure when it is at least 60%, by weight, free from the proteins and naturally-occurring organic molecules with which it is naturally associated.
  • the preparation is at least 75%, more preferably at least 90%. and most preferably at least 99%, by weight, a polypeptide of the invention.
  • a substantially pure protein of the invention may be obtained, for example, by extraction from a natural source (for example, a virus), by expression of a recombinant nucleic acid encoding such a protein, or by chemically synthesizing the protein. Purity can be measured by any appropriate method, for example, column chromatography. polyacrylamide gel electrophoresis. or by HPLC analysis.
  • substantially pure polypeptides include those derived from eukaryotic organisms but synthesized in E. coli or other prokaryotes.
  • substantially pure nucleic acid is meant a nucleic acid (e.g., DNA) that is free of the genes, or transcripts thereof, which, in the naturally-occurring genome of the organism from which the nucleic acid of the invention is derived, flank the gene.
  • the term therefore includes, for example, a recombinant DNA which is incorporated into a vector; into an autonomously replicating plasmid or virus: or into the genomic DNA of a prokaryote or eukaryote; or which exists as a separate molecule (e.g., a cDNA or a genomic or cDNA fragment produced by PCR or restriction endonuclease digestion) independent of other sequences.
  • the term includes an RNA molecule which is transcribed from a DNA molecule, as well as a recombinant DNA which is part of a hybrid gene encoding additional polypeptide sequence.
  • E4orf4 protein is meant a polypeptide product encoded by nucleic acid capable of hybridizing at high stringency conditions to a nucleic acid molecule encoding E4orf4 and having at least one E4orf4 biological activity. It will be understood that E4orf4 proteins and nucleic acids of the invention may be obtained from any adenovirus strain having the E4orf4 open reading frame, as defined as an open reading frame which is at least 20%, preferably 50%. more preferably 75%, and most preferably 90% identity to the E4orf4 open reading frame of adenovirus serotype Ad2, Ad5, Ad 12, or Ad40.
  • PP2A or "protein phosphatase 2A” is meant a polypeptide product encoded by nucleic acid capable of hybridizing at high stringency conditions to a nucleic acid molecule encoding a PP2A subunit which, when combined with other subunits, has at least one PP2A biological activity.
  • a preferred PP2A biological activity is dephosphorylation of a PP2A substrate.
  • PP2A consists of three subunits (A, B. and C). It will be understood that PP2A proteins and nucleic acids of the invention may be obtained from any source having a PP2A open reading frame, as defined as an open reading frame which is at least 20%, preferably 50%. more preferably 75%, and most preferably 90% identity to the PP2A open reading frame of human PP2A or S. cerevisiae CDC55.
  • Sequence identity is typically measured using sequence analysis software with the default parameters specified therein (e.g. , Sequence Analysis Software Package of the Genetics Computer Group, University of Wisconsin Biotechnology Center, 1710 University Avenue, Madison, WI 53705, BLAST, or PILEUP PRETTYBOX programs).
  • the E4orf4 protein has the consensus sequence shown in Fig. 1, where X can be any amino acid residue.
  • high stringency conditions is meant conditions that allow DNA hybridization to nucleic acids encoding E4orf4 at high stringency (e.g., hybridizing in 2X SSC at 40°C with a DNA probe length of at least 40 nucleotides). For other definitions of high stringency conditions, see Ausubel, F. et al.. 1994, Current Protocols in Molecular Biology, John Wiley & Sons. New York, 6.3.1 - 6.3.6, hereby incorporated by reference.
  • E4orf4 biological activity binding to the B subunit of PP2A, modulating PP2A biological activity, and specifically inducing, in tumor cells, biological processes that result in cell death.
  • PP2A biological activity is meant dephosphorylation of serine or threonine residues of PP2A substrates.
  • PP2A substrates include, for example. Rb protein, Bcl-2. vimentin. casein-kinase II, and SR proteins. Those in the art will recognize that there are other PP2A substrates.
  • interact or "bind” is meant that two polypeptides can transitorily bind, either directly or indirectly, to each other. Indirect binding can take place, for example, through the formation of a multi-protein complex. The interaction is dependent on inherent properties of the two polypeptides. and specifically excludes non-specific (e.g., strictly Brownian) contact. Preferably, this interaction can be disrupted or prevented by alteration in the primary, secondary, or tertiary structure of one or both of the polypeptides.
  • Expose is meant to allow contact between an animal, cell, lysate. or extract derived from a cell, or molecule derived from a cell, and a candidate compound.
  • treat is meant to submit or subject an animal (e.g. a human), cell, lysate or extract derived from a cell, or molecule derived from a cell to a candidate compound.
  • test compound is meant a chemical, be it naturally-occurring or artificially-derived, that is assayed for its ability to modulate an alteration in reporter gene activity or protein levels, by employing one of the assay methods described herein.
  • Test compounds may include, for example, peptides, polypeptides, synthesized organic molecules, naturally occurring organic molecules, nucleic acid molecules, and components thereof.
  • assaying is meant analyzing the effect of a treatment, be it chemical or physical, administered to whole animals or cells derived therefrom.
  • the material being analyzed may be an animal, a cell, a lysate or extract derived from a cell, or a molecule derived from a cell. The analysis may be.
  • the means for analyzing may include, for example, antibody labeling, immunoprecipitation. phosphorylation assays, and methods known to those skilled in the art for detecting nucleic acids and polypeptides.
  • modulating is meant changing, either by decrease or increase. biological activity.
  • a decrease is meant a lowering in the level of biological activity, as measured by a lowering of (i) PP2A protein, as measured by ELISA; (ii) PP2A phosphatase activity, as measured, for example, by standard techniques; (iii) PP2A mRNA levels, as measured by PCR relative to an internal control, for example, a "housekeeping" gene product such as ⁇ -actin or glyceraldehyde 3-phosphate dehydrogenase (GAPDH); (iv) the amount of E4orf4 (or any other protein that is part of a protein complex that contains E4orf4) that interact with PP2A; and (v) PP2A-mediated cell killing.
  • the lowering is preferably by 20%, more preferably by 40%, and even more preferably by 70%.
  • an increase is meant a rise in the level of biological activity, as measured by an increase of: (i) PP2A protein, as measured by ELISA; (ii) PP2A phosphatase activity, as measured, for example, by standard techniques; (iii) PP2A mRNA levels, as measured by PCR relative to an internal control, for example, a "housekeeping" gene product such as ⁇ -actin or glyceraldehyde 3-phosphate dehydrogenase (GAPDH); (iv) the amount of E4orf4 ⁇ or any other protein that is part of a protein complex that contains E4orf4) that interact with PP2A; and (v) PP2A-mediated cell killing.
  • PP2A protein as measured by ELISA
  • PP2A phosphatase activity as measured, for example, by standard techniques
  • PP2A mRNA levels as measured by PCR relative to an internal control, for example, a "housekeeping" gene product such as ⁇ -
  • the increase is by 5% or more, more preferably by 15% or more, even more preferably by 2-fold, and most preferably by at least 3-fold.
  • transfection is meant any method for introducing foreign molecules into a cell. Lipofection, calcium phosphate precipitation, retroviral delivery, electroporation, and biolistic transformation are just a few of the teachings which may be used.
  • pharmaceutically acceptable carrier is meant a carrier that is physiologically acceptable to the treated mammal while retaining the therapeutic properties of the compound with which it is administered.
  • One exemplary pharmaceutically acceptable carrier is physiological saline.
  • Other physiologically acceptable carriers and their formulations are known to one skilled in the art and described, for example, in Remington: The Science and Practice of Pharmacy, ( 19th ed.) ed. A.R. Gennaro AR., 1995, Mack Publishing Company. Easton. PA.
  • protein or “polypeptide” is meant any chain of amino acids, regardless of length or post-translational modification (for example, glycosylation or phosphorylation).
  • Fig. 1 is a schematic illustration showing alignment of E4orf4 proteins from adenovirus serotypes (Ad5. Ad9, Ad 12, and Ad40). The consensus sequence of adenovirus E4orf4 is shown as the top sequence.
  • Fig. 2 is a schematic illustration of the various residues that were point mutated in Ad2 serotype E4orf4. Each of the indicated residues was mutated to alanine, such that, for example, the P4 mutant has an alanine residue at position 4 instead of proline.
  • Fig. 3 is a photograph of an anti-HA Western blotting analysis showing the expression of the Ad2 E4orf4 point mutants (and wild-type controls) in whole cell extracts (WCE) of C33A cells transfected with the hemagglutinin (HA)-tagged Ad2 E4orf4 point mutants.
  • Fig. 4A is a schematic illustration depicting the PP2A/E4orf4 complex. Note the hemagglutinin (HA) tag on E4orf4 and the Flag-tag on the B ⁇ subunit of PP2A.
  • Fig. 4B is a schematic diagram of the steps involved in the immunoprecipitation of HA-tagged E4orf4. followed by an in vitro phosphatase assay; a whole cell extract followed by immunoblotting; or a drug resistant colony assay, following the co-transfection of cells with an HA- tagged E4orf4 mutant a Flag-tagged B ⁇ subunit of PP2A.
  • HA hemagglutinin
  • Fig. 4C is a schematic illustration showing the results of the in vitro phosphatase assay following HA-tagged E4orf4 immunoprecipitation from cells co-transfected with Flag-tagged B ⁇ subunit of PP2A and the indicated HA-tagged E4orf4 mutant (or mock transfected).
  • Fig. 4D is a photograph of Western blotting analysis of the SDS-PAGE resolved samples that were assayed for in vitro phosphatase activity in the experiment shown in Fig. 4C (E4orf4 IP lane) using an anti-Flag antibody, which detected the Flag-tagged PP2A B ⁇ subunit.
  • the WCE lane is a Western blotting analysis of whole cell extracts from transfected cells.
  • Fig. 5 is a schematic illustration of the areas in E4orf4 that are important for binding to PP2A B ⁇ subunit and/or important for suppressing colony formation of transfected cells. These areas are shown in diagram of the linear E4orf4 amino acid sequence. Areas in solid black bars indicate the areas of E4orf4 which, when mutated, result in a loss of binding of E4orf4 to PP2A B ⁇ subunit and a loss of phosphatase activity of PP2A (which is lost since it is no longer associated with these E4orf4 mutants), and do not result in any suppression of colony formation of cells stably transfected with the E4orf4 mutant.
  • Areas in diagonal hatch bars indicate the areas of E4orf4 that, when mutated, result in a partial loss of binding of E4orf4 to PP2A B ⁇ subunit. a partial loss of phosphatase activity of associated PP2 A. and a partial suppression of colony formation of stably transfected cells.
  • Areas in horizontal hatch bars indicate the areas of E4orf4 that, when mutated, result in a normal (wild-type) binding of E4orf4 to PP2A B ⁇ subunit, wild-type levels of phosphatase activity of associated PP2A, and a partial suppression of colony formation of stably transfected cells.
  • Fig. 6 is a schematic illustration of relative cell death of indicated cell lines stably transfected with an inactive E4orf4 mutant (white bars outlined in black), wild-type E4orf4 (black bars), or Bax (stippled bars).
  • Fig. 7 is a schematic illustration how the tetracycline-inducible E4orf4- encoding virus (Ad5-TindHAorf4) was constructed. Also shown in this diagram is the construction strategy used to generate a virus expressing the reverse tet-transactivator operably linked to the CMV promoter (Ad5- CMVrtTA).
  • Fig. 8 is a photograph of an immunoblot showing inducible E4orf4 expression with the Ad5-TindHAorf4 virus.
  • Mrc-5, HeLa. or C33A cells were infected (+) with Ad5-TindHAorf4 and Ad5-CMVrtTA.
  • HA-tagged E4orf4 (detected by anti-HA antibody) was induced by addition to the infected cells of 10 ⁇ g/ml doxycycline.
  • Fig. 9 is a series of photographs of Western blots showing the dose- and temporal-response to doxycycline.
  • Fig. 10 is a schematic illustration showing that E4orf4 inhibits growth of HI 299 lung carcinoma cells.
  • Fig. 11 is a series of schematic illustrations showing that E4orf4 inhibits growth of HI 299 and C33A tumor cell lines.
  • Fig. 12 is a series of schematic illustrations showing that E4orf4 does not inhibit growth of HMEC or NHDF cells, two normal primary cells.
  • Figs. 13A and 13B are a series of photographs showing the effect of E4orf4 protein expression on yeast colony growth.
  • Figs. 14A and 14B are a series of photographs showing that yeast expressing E4orf4 are viable.
  • Haploid yeast containing either vector alone or HA-E4orf4 were grown in glucose-based medium. Cells were transferred to glucose or galactose and aliquots of cells were removed at various times post-induction and the percentage of cells excluding trypan blue was determined (Fig. 14A).
  • Whole cell extracts were prepared from cells collected at the indicated times and subject to immunoblot assay using anti-HA antibody (Fig. 14B).
  • Fig. 15A- 15C are a series of photographs showing that E4orf4 expression in wild-type yeast confers an elongated cell morphology.
  • Yeast transformed with vector alone (Fig. 15 A) or E4orf4 (Fig. 15B) were cultured in galactose-based medium at 30?C.
  • the cdc55 strain was grown in galactose medium at 18?C (Fig. 15C).
  • Figs. 16A and 16B are a serues of photographs showing that E4orf4 requires Cdc55 to induce the slow growth phenotype. Wild-type and cdc55 cells were transformed with vector or E4orf4.
  • FIG. 16A Whole cell extracts prepared from yeast cells collected from the above plates were subject to SDS-PAGE immunoblot assay using anti-HA antibody (Fig. 16B). Lanes 1 and 3 represent vector alone and lanes 2 and 4 represent E4orf4 expression.
  • Figs. 17A- 17F are a series of photographs showing that E4orf4 requires Cdc55 to recruit the PP2A complex.
  • the cdc55 strain was co-transformed with the indicated plasmids (pYES2. p424GALl. pYes2-HAE4orf4 or p424GAL-FlagCDC55) and whole cell extracts were prepared 24 hours post-galactose induction. Extracts were incubated with anti-HA or anti-Flag antibodies. Immunoprecipitates were separated by SDS-PAGE and subject to immunoblotting with anti-HA (Figs. 17A and 17D), anti-Flag (Figs.
  • Figs. 18A- 18I are a series of photographs showing E4orf4 can imrnunoprecipitate PP2A complexes containing both forms of the yeast catalytic subunit. 1. v+v; 2. V+PPH21; 3. V+PPH22; 4. E4orf4+v; 5. E4orf4+PPH21 ; 6. E4orf4+PPH22. Wild-type yeast were co-transformed with plasmids expressing the indicated proteins and cells were collected 24 hours post-galactose induction.
  • Figs. 18A and 18D Whole cell extracts (wee) were prepared and subject to immunoprecipitation with antibody against the Flag or HA epitope. Proteins were separated by SDS PAGE followed by Western blotting with anti-HA (Figs. 18A and 18D), anti-Flag (Figs. 18B and 18E), or anti-Tpd3 antibodies (Figs. 18C and 18E). Protein expression from wee was also determined (Figs. 18G-18I).
  • Figs. 19A-19C are a series of photographs showing analysis of colony growth and Cdc55 binding using E4orf4 point mutants.
  • Fig. 19 A shows yeast transformed with plasmids expressing the indicated HA-tagged proteins and spotted onto glucose- or galactose-based medium and incubated at 30?C.
  • Fig. 19B shows anti-HA western blot of whole cell extracts prepared from cells expressing the indicated proteins.
  • Fig. 19C shows co-immunoprecipitation experiments using whole cell extracts prepared from the cdc55 strain transformed with the indicated plasmids; CDC55 is Flag-tagged.
  • Figs. 20A and 20B are a series of photographs showing that the slow growth effect of E4orf4 in yeast specifically requires CDC55 and not RTSI .
  • wild-type or RTS I deleted cells were transformed with vector, E4orf4 or E4orf4 point mutants.
  • Serial dilutions of cultured cells were spotted onto glucose or galactose-based agar plates, and photographs were taken on day 3 post-incubation.
  • Fig. 20B shows whole cell extracts immunoblotted for the HA-epitope to confirm protein expression.
  • Detailed Description of the Invention We have found a correlation between binding of E4orf4 to PP2A and E4orf4-mediated apoptosis.
  • E4orf4 selectively associates with PP2A.
  • an E4orf4 mutant having an ability to more tightly associate with PP2A B ⁇ subunit may be able to induce a more rapid cell death in a neoplastic cell ⁇ e.g., C33A) while not killing a non- neoplastic cell (e.g., Mrc-5).
  • This association may be exploited for screening compounds, such as polypeptide or chemical compounds that bind to PP2A and selectively kill neoplastic cells, while not killing non-neoplastic cells, in various in vivo and in vitro contexts.
  • Mutant PP2A proteins or PP2A mimetics may also be developed, using the teachings described herein, which have an enhanced ability to kill neoplastic cells, while retaining an inability to kill normal cells.
  • S. cerevisae is useful for performing high-throughput screens for the identification of compounds that modulate or mimic E4orf4 interactions with PP2A.
  • the E4orf4 proteins, mutants, or mimetics thereof of the invention may be recombinantly produced in a cell transfected with an expression plasmid.
  • the invention provides substantially purified DNA encoding E4orf4 proteins, mutants, or analogs thereof.
  • the invention provides a vector (e.g., an adenoviral vector) encoding an E4orf4 protein (or mutant thereof).
  • the viruses lacking an E1B-19K protein, described in U.S. Patent No. 5,667.178, are specifically excluded from the present invention.
  • the vector is genetically engineered.
  • E4orf4-encoding adenoviruses of the invention may be manipulated using the techniques and assays provided in U.S. Patent No. 5,667, 178 (issued October 14, 1997) or PCT Application No. PCT IB97/01041 (published January 15, 1998), both of which are incorporated by reference.
  • E4orf4 and PP2A polypeptides For protein expression, eukaryotic and prokaryotic expression systems may be generated in which nucleic acid sequences are introduced into a plasmid or other vector, which is then used to transform living cells. Constructs in which cDNA containing the entire open reading frames encoding E4orf4 or a PP2A subunit, inserted in the correct orientation into an expression plasmid, may be used for protein expression. Alternatively, portions of the nucleic acid sequences, including those encoding wild-type or mutant E4orf4 or PP2A subunits, may be inserted.
  • Prokaryotic and eukaryotic expression systems allow various important functional domains of the proteins to be recovered as fusion proteins and then used for binding, structural and functional studies and also for the generation of appropriate antibodies. Since expression of E4orf4 and PP2A polypeptides may induce cell death in some cell types (e.g., tumor cells), it may be desirable to express the protein under the control of an inducible promoter, as described herein.
  • Typical expression vectors contain promoters that direct the synthesis of large amounts of mRNA corresponding to the inserted nucleic acid in the plasmid bearing cells. They may also include eukaryotic or prokaryotic origin of replication sequences which allow for their autonomous replication within the host organism, sequences that encode genetic traits that allow vector- containing cells to be selected for in the presence of otherwise toxic drugs, and sequences that increase the efficiency with which the synthesized mRNA is translated. Stable long-term vectors may be maintained as freely replicating entities by using regulatory elements of. for example, viruses (e.g., the OriP sequences from the Epstein Barr Virus genome). Cell lines may also be produced which have integrated the vector into the genomic DNA. and in this manner the gene product is produced on a continuous basis.
  • viruses e.g., the OriP sequences from the Epstein Barr Virus genome
  • Expression of foreign sequences in bacteria requires the insertion of the nucleic acid sequence into a bacterial expression vector.
  • This plasmid vector contains several elements required for the propagation of the plasmid in bacteria, and expression of inserted DNA of the plasmid by the plasmid-carrying bacteria. Propagation of only plasmid-bearing bacteria is achieved by introducing in the plasmid selectable marker-encoding sequences that allow plasmid-bearing bacteria to grow in the presence of otherwise toxic drugs.
  • the plasmid also bears a transcriptional promoter capable of producing large amounts of mRNA from the cloned gene.
  • Such promoters may or may not be inducible promoters, which initiate transcription upon induction.
  • the plasmid also preferably contains a polylinker to simplify insertion of the gene in the correct orientation within the vector.
  • the expression vector plasmid contains a fragment of the E. coli chromosome containing the lac promoter and the neighboring lacZ gene.
  • the lactose analog IPTG.
  • RNA polymerase normally transcribes the lacZ gene, producing lacZ mRNA. which is translated into the encoded protein, ⁇ -galactosidase.
  • the lacZ gene can be cut out of the expression vector with restriction endonucleases and replaced by an E4orf4 or PP2A nucleic acid sequence, or fragment, fusion, or mutant thereof.
  • E4orf4 or PP2A nucleic acid sequence or fragment, fusion, or mutant thereof.
  • this resulting plasmid is transfected into E. coli, addition of IPTG and subsequent transcription from the lac promoter produces mRNA, which is translated into an E4orf4 or PP2A polypeptide.
  • the appropriate expression vectors containing an E4orf4 or PP2A gene, or fragment, fusion, or mutant thereof, are constructed, they are introduced into an appropriate host cell by transformation techniques including, for example, calcium phosphate transfection, DEAE-dextran transfection. electroporation, rmcroinjection. protoplast fusion and liposome- mediated transfection. as described herein.
  • the host cells that are transfected with the vectors of this invention may include (but are not limited to) E. coli. Pseudomonas, Bacillus subtilus. or other bacilli, other bacteria, yeast, fungi, insect (using, for example, baculoviral vectors for expression), mouse or other animal or human tissue cells. Mammalian cells can also be used to express protein using a vaccinia virus expression system described in Ausubel et al., 1997, Current Protocols in Molecular Biology, Wiley Interscience, New York.
  • T7 late-promoter expression system In vitro expression of E4orf4 and PP2A proteins, fusions, polypeptide fragments, or mutants encoded by cloned DNA is also possible using the T7 late-promoter expression system.
  • T7 RNA polymerase which is an enzyme encoded in the DNA of bacteriophage T7.
  • the T7 RNA polymerase transcribes DNA beginning within a specific 23-bp promoter sequence called the T7 late promoter. Copies of the T7 late promoter are located at several sites on the T7 genome, but none is present in E. coli chromosomal DNA.
  • T7 RNA polymerase catalyzes transcription of viral genes but not of E.
  • E. coli cells are first engineered to carry the gene encoding T7 RNA polymerase next to the lac promoter. In the presence of IPTG. these cells transcribe the T7 polymerase gene at a high rate and synthesize abundant amounts of T7 RNA polymerase. These cells are then transformed with plasmid vectors that carry a copy of the T7 late promoter protein. When IPTG is added to the culture medium containing these transformed E. coli cells, large amounts of T7 RNA polymerase are produced. The polymerase then binds to the T7 late promoter on the plasmid expression vectors, catalyzing transcription of the inserted cDNA at a high rate. Since each E.
  • coli cell contains many copies of the expression vector, large amounts of mRNA corresponding to the cloned cDNA can be produced in this system and the resulting protein can be radioactively labeled.
  • Plasmid vectors containing late promoters and the corresponding RNA polymerases from related bacteriophages such as T3, T5, and SP6 may also be used for in vitro production of proteins from cloned DNA.
  • E. coli can also be used for expression using an M13 phage such as mGPI-2.
  • vectors that contain phage lambda regulatory sequences or vectors that direct the expression of fusion proteins, for example, a maltose-binding protein fusion protein or a glutathione-S-transferase fusion protein, also may be used for expression in E. coli.
  • Eukaryotic expression systems permit appropriate post-translational modifications to expressed proteins. Transient transfection of a eukaryotic expression plasmid allows the transient production of a polypeptide by a transfected host cell. E4orf4 and PP2A proteins may also be produced by a stably-transfected mammalian cell line.
  • cDNA encoding an E4orf4 or PP2A protein, fusion, mutant, or polypeptide fragment is cloned into an expression vector that includes the dihydrofolate reductase (DHFR) gene.
  • DHFR dihydrofolate reductase
  • Integration of the plasmid and, therefore, integration of the protein-encoding nucleic acid sequence into the host cell chromosome is selected for by inclusion of 0.01-300 ⁇ M methotrexate in the cell culture medium (as described in Ausubel et al.. supra). This dominant selection can be accomplished in most cell types. Recombinant protein expression can be increased by DHFR-mediated amplification of the transfected gene. Methods for selecting cell lines bearing gene amplifications are described in Ausubel et al.. supra. These methods generally involve extended culture in medium containing gradually increasing levels of methotrexate.
  • DHFR-containing expression vectors are pCVSEII-DHFR and pAdD26SV(A) (described in Ausubel et al.. supra).
  • the host cells described above or. preferably, a DHFR-deficient CHO cell line e.g., CHO DHFR " cells. ATCC Accession No. CRL 9096
  • a DHFR-deficient CHO cell line e.g., CHO DHFR " cells. ATCC Accession No. CRL 9096
  • Eukaryotic cell expression of E4orf4 and PP2A proteins allows the production of large amounts of normal and mutant proteins for isolation and purification, and the use of cells expressing these proteins as a functional assay system for antibodies generated against the protein. Eukaryotic cells expressing one or both of these proteins may also be used to test the effectiveness of pharmacological agents on E4orf4/PP2A-mediated biological activity (e.g., killing of tumor cells), or as means by which to study E4orf4 and PP2A proteins as components of a signal transduction pathway.
  • E4orf4 and PP2A DNA sequences can be altered using procedures known in the art, such as restriction endonuclease digestion, DNA polymerase fill-in. exonuclease deletion, terminal deoxynucleotide transferase extension, ligation of synthetic or cloned DNA sequences and site- directed sequence alteration using specific oligonucleotides together with PCR.
  • Another preferred eukaryotic expression system is the baculovirus system using, for example, the vector pBacPAK9, which is available from Clontech (Palo Alto, CA). If desired, this system may be used in conjunction with other protein expression techniques, for example, the myc tag approach described by Evan et al. (Mol. Cell Biol. 5:3610-3616, 1985).
  • the recombinant protein can be isolated from the expressing cells by cell lysis followed by protein purification techniques, such as affinity chromatography.
  • protein purification techniques such as affinity chromatography.
  • an anti-E4orf4 antibody can be attached to a column and used to isolate the recombinant E4orf4 proteins. Lysis and fractionation of E4orf4 protein-harboring cells prior to affinity chromatography may be performed by standard methods (see e.g., Ausubel et al., supra).
  • the recombinant protein can, if desired, be purified further by e.g., by high performance liquid chromatography (HPLC; e.g., see Fisher, Laboratory Techniques In Biochemistry And Molecular Biology, Work and Burdon, Eds., Elsevier, 1980).
  • HPLC high performance liquid chromatography
  • Polypeptides of the invention can also be produced by chemical synthesis (e.g., by the methods described in Solid Phase Peptide Synthesis, 2nd ed., 1984, The Pierce Chemical Co., Rockford, IL). These general techniques of polypeptide expression and purification can also be used to produce and isolate useful E4orf4 polypeptide fragments or analogs, as described herein. Those skilled in the art of molecular biology will understand that a wide variety of expression systems may be used to produce the recombinant E4orf4 and PP2A proteins. The precise host cell used is not critical to the invention.
  • the proteins may be produced in a prokaryotic host (e.g., E. coli) or in a eukaryotic host (e.g., S. cerevisiae, insect cells such as Sf9 cells, or mammalian cells such as COS-1, NIH 3T3, or HeLa cells). These cells are commercially available from, for example, the American Type Culture Collection, Rockville, MD (see also Ausubel et al., supra).
  • the method of transformation and the choice of expression vehicle will depend on the host system selected. Transformation and transfection methods are described, e.g., in Ausubel et al., supra, and expression vehicles may be chosen from those provided, e.g. in Pouwels et al., supra.
  • E4orf4 allows the study of E4orf4 biological activity.
  • administration of an E4orf4 protein, or a polypeptide fragment thereof may have an ability to modulate PP2A biological activity (e.g., phosphatase activity), as measured by cell-based and cell-free assays known in the art and described herein, and/or kill tumor cells.
  • PP2A biological activity e.g., phosphatase activity
  • assays may be carried out in a cell which either expresses endogenous PP2A or a cell to which is introduced a heterologous amount of a PP2A polypeptide or in a cell-free assay.
  • the cell is capable of undergoing E4orf4-mediated cell death.
  • E4orf4 biological activity is binding of E4orf4 to the B subunit of PP2A. It is understood that the binding may not be through direct contact between E4orf4 and PP2A. but may require additional proteins. Binding of E4orf4 to PP2A. or any other protein that is part of a protein complex that contains PP2A, can be measured using any of a number of standard methods known to those in the art, such as the methods described herein. Another preferred E4orf4 biological activity is the specific killing of tumor cells. The killing of cells is very likely to require binding to PP2A. Thus a compound that binds to PP2A should also be screened for its ability to kill tumor cells.
  • novel drugs that mimic E4orf4 biological activity or modulate or mimic PP2A biological activity are identified from large libraries of both natural product or synthetic (or semi-synthetic) extracts or chemical libraries according to methods known in the art.
  • test extracts or compounds are not critical to the screening procedure(s) of the invention. Accordingly, virtually any number of chemical extracts or compounds can be screened using the exemplary methods described herein.
  • extracts or compounds include, but are not limited to, plant-, fungal-, prokaryotic- or animal-based extracts, fermentation broths, and synthetic compounds, as well as modification of existing compounds. Numerous methods are also available for generating random or directed synthesis (e.g., semi-synthesis or total synthesis) of any number of chemical compounds, including, but not limited to. saccharide-, lipid-, peptide-, and nucleic acid-based compounds. Synthetic compound libraries are commercially available from Brandon Associates (Merrimack, NH) and Aldrich Chemical (Milwaukee, WI).
  • libraries of natural compounds in the form of bacterial, fungal, plant, and animal extracts are commercially available from a number of sources, including Biotics (Sussex, UK), Xenova (Slough, UK), Harbor Branch Oceangraphics Institute (Ft. Pierce, FL), and PharmaMar, U.S.A. (Cambridge, MA).
  • Biotics Sussex, UK
  • Xenova Slough, UK
  • Harbor Branch Oceangraphics Institute Ft. Pierce, FL
  • PharmaMar, U.S.A. Chembridge, MA
  • natural and synthetically produced libraries are produced, if desired, according to methods known in the art, e.g., by standard extraction and fractionation methods.
  • any library or compound is readily modified using standard chemical, physical, or biochemical methods.
  • the effect of candidate compounds on E4orf4/PP2A-mediated regulation of cell death may be measured at the level of PP2A phosphatase activity by using the general approach described above with standard protein detection techniques, such as Western blotting or immunoprecipitation with a PP2A-specific antibody.
  • E4orf4 biological activity or modulate or mimic PP2A biological activity may be purified, or substantially purified, or may be one component of a mixture of compounds such as an extract or supernatant obtained from cells (Ausubel et al., supra).
  • E4orf4 or PP2A biological activity is measured in cells administered progressively smaller subsets of the compound pool (e.g., produced by standard purification techniques such as HPLC or FPLC) until a single compound or minimal number of effective compounds is demonstrated to mimic E4orf4 biological activity or modulate or mimic PP2A biological activity.
  • the degree of biological activity in the presence of a candidate compound is compared to the degree of biological activity in its absence, under equivalent conditions.
  • Biological activity may be measured by any standard assay, for example, those described herein.
  • Another method for detecting compounds that modulate the activity of PP2A is to screen for compounds that bind to PP2A.
  • These compounds may be detected by adapting interaction trap expression systems known in the art. These systems detect protein interactions using a transcriptional activation assay and are generally described by Gyuris et al. (Cell 75:791-803, 1993) and Field et al., (Nature 340:245-246, 1989), and are commercially available from Clontech (Palo Alto, CA).
  • compounds that bind to PP2A can be isolated by column chromatography. In this assay, candidate compounds or extracts are passed through a column containing immobilized PP2A B subunit or PP2A holoprotein.
  • an E4orf4 analog is one that cannot kill (or exhibits a decrease in killing) in the absence of PP2A biological activity. Those in the art will recognize that any strategy that decreases PP2A biological activity is useful in the present invention.
  • E4orf4 polypeptides that are partially defective for colony suppression, but wild-type for binding to PP2A. These polypeptides as dominant- negative E4orf4 polypeptides and are useful as competitive reagents for identifying compounds that kill by binding to PP2A in a manner similar to that of PP2A.
  • one series of assays include determining the ability the compounds, known to be toxic, to kill cells expressing a dominant-negative E4orf4 polypeptide.
  • Dominant-negative PP2A polypeptides can also be made.
  • PP2A A subunit mutants can be made which fail to interact with specific B subunits, but which still bind to the catalytic C subunit.
  • the small T antigens of polyomavirus and SV40 virus and the middle T antigen of polyomavirus interact with the PP2A A subunit, also inhibiting interactions with the B subunit, which is the likely mechanism of E4orf4/PP2A-mediated killing of tumor cells.
  • a cell line that lacks functional PP2A B ⁇ subunit can be made using standard homologous recombination techniques. It is likely that generation of a mouse lacking PP2A B ⁇ subunit will not be viable, but cell lines derived from embryonic stem cells may be produced. If necessary, the deleted gene can be complemented with a copy of the gene under the control of an inducible promoter, such that cells may be grown in the presence of functional enzyme, but the assays performed in the absence of functional enzyme. Antisense based strategies may be employed to reduce PP2A biological activity. The principle is based on the hypothesis that sequence-specific suppression of gene expression can be achieved by intracellular hybridization between mRNA and a complementary antisense species.
  • Antisense strategies may use a variety of approaches including the use of antisense oligonucleotides and injection of antisense RNA.
  • Antisense effects can be induced by control (sense) sequences, however, the extent of phenotypic changes are highly variable. Phenotypic effects induced by antisense effects are based on changes in criteria such as protein levels, protein activity measurement, and target mRNA levels. Reduction of PP2A biological activity may be accomplished by direct administration of antisense PP2A mRNA to a cell in which proliferation is desired.
  • the antisense PP2A mRNA may be produced and isolated by any standard technique, but is most readily produced by in vitro transcription using an antisense PP2A cDNA under the control of a high efficiency promoter (e.g., the T7 promoter).
  • Administration of antisense PP2A mRNA to cells can be carried out by any of the methods for direct nucleic acid administration described above.
  • An alternative strategy for decreasing PP2A biological activity involves intracellular expression of an anti-PP2A antibody or a portion of an anti-PP2A antibody.
  • a nucleic acid (or fragment thereof) encoding a monoclonal antibody that specifically binds to PP2A and inhibits its biological activity may be placed under the transcriptional control of a cell type-specific gene regulatory sequence.
  • PP2A is actively involved in the cell killing, by causing one or more dephosphorylation events. This may be due to an increase in overall PP2A phosphatase activity such that all PP2A substrates are dephosphorylated at an increased rate. Alternatively, it may be due to that one or a subset of PP2A substrates are dephosphorylated at an increased rate.
  • This second, selective, increase may be due to a conformational change in the PP2A holoenzyme, leading to enhanced enzyme-substrate interactions.
  • E4orf4 may target PP2A to specific substrates by altering the subcellular localization of PP2A.
  • a death-inducing protein could be activated, or a survival factor could be inactivated, by dephosphorylation.
  • E4orf4 by binding to PP2A, may interfere with the ability of PP2A to perform a dephosphorylation function.
  • E4orf4 could alter the subcellular localization of PP2A, making it no longer accessible to a substrate; (ii) a substrate could be displaced by E4orf4, or its binding site could be blocked; or (iii) E4orf4 binding to PP2A could induce a conformational change in PP2A that reduces its affinity for a substrate. In each of the three cases, the interference could be generally to all PP2A substrates, or it could be restricted to one or a subset of PP2A substrates.
  • E4orf4/PP2A interactions Several pathways are affected by E4orf4/PP2A interactions.
  • E4orf4/PP2A interaction causes alterations in the activity of several transcriptions, including, for example, AP- 1, E4F, ATF-2, and El A.
  • splicing changes induced by an alteration in the activity of a splicing regulator is likely, as E4orf4/PP2A interactions alter the splicing pattern of late viral mRNAs through the dephosphorylation of SR proteins, which are splicing regulators.
  • Bcl-2 a core apoptosis inhibitor, is both positively and negatively regulated by phosphorylation.
  • the Bad death-promoter is inactivated by phosphorylation, while two kinases involved in inactivating Bad (PDK1 and AKT) are activated via phosphorylation.
  • PDK1 and AKT two kinases involved in inactivating Bad
  • an increase in Bad dephosphorylation or a decrease in PDK1 or AKT dephosphorylation may lead to cell death.
  • alteration in the MAP kinase growth signaling pathway is suppressed by E4orf4/PP2A complexes. This is likely to lead to a decrease in growth and survival signals.
  • Molecules that mimic E4orf4 biological activity or modulate or mimic PP2A biological activity are considered useful in the invention; such molecules may be used, for example, as a therapeutic in the treatment of neoplasms or other cell proliferative diseases.
  • E4orf4 or PP2A polypeptide to add an E4orf4 or PP2A polypeptide to cells in order to modulate cell proliferation or apoptosis, it is preferable to obtain pure E4orf4 or PP2A protein from cultured cell systems that can express the protein. Delivery of the protein to the affected tissue can then be accomplished using appropriate packaging or administrating systems.
  • small molecule analogs may be used and administered to act as E4orf4 or PP2A agonists and in this manner produce a desired physiological effect. Methods for finding such molecules are provided herein.
  • Gene therapy is another potential therapeutic approach in which nucleic acid encoding E4orf4 or PP2A sense RNA is introduced into cells.
  • the gene must be delivered to those cells in a form in which it can be taken up and encode for sufficient protein to provide effective function.
  • Transducing retroviral, adenoviral, and human immunodeficiency viral (HIV) vectors can be used for somatic cell gene therapy especially because of their high efficiency of infection and stable integration and expression (see, for example, Cayouette and Gravel, Hum. Gene Ther., 8:423-430, 1997; Kido et al. Curr. Eye Res., 15:833-844, 1996; Bloomer et al., J. Virol., 71 :6641-6649, 1997; Naldini et al., Science 272:263-267, 1996; Miyoshi et al., Proc. Natl. Acad. Sci. USA, 94: 10319-10323, 1997).
  • HIV human immunodeficiency viral
  • the full length E4orf4 nucleic acid, or portions thereof can be cloned into a retroviral vector and driven from its endogenous promoter or from the retroviral long terminal repeat or from a promoter specific for the target cell type of interest (such as neurons).
  • viral vectors which can be used include adenovirus, adeno- associated virus, vaccinia virus, bovine papilloma virus, or a herpes virus such as Epstein-Barr Virus.
  • Gene transfer could also be achieved using non-viral means requiring infection in vitro. This would include calcium phosphate, DEAE dextran,
  • SUBSTTTUTE SHEET (RULE 26) electroporation, and protoplast fusion. Liposomes may also be potentially beneficial for delivery of DNA into a cell. Although these methods are available, many of these are of lower efficiency.
  • Transplantation of normal genes into the affected cells of a patient can also be useful therapy.
  • an E4orf4 nucleic acid sequence is transferred into a cultivatable cell type, either exogenously or endogenously to the patient. These cells are then injected into the targeted tissue(s).
  • expression can be directed from any suitable promoter (e.g., the human cytomegalovirus (CMV), simian virus 40 (SV40), or metallothionein promoters), and regulated by any appropriate mammalian regulatory element.
  • CMV human cytomegalovirus
  • SV40 simian virus 40
  • metallothionein promoters e.g., metallothionein promoters
  • enhancers known to preferentially direct gene expression in tumor cells may be used to direct E4orf4 expression.
  • the enhancers used could include, without limitation, those that are characterized as tissue- or cell-specific in their expression.
  • E4orf4 polypeptide e.g, the one described herein
  • the dosage of E4orf4 or analog depends on a number of factors, including the size and health of the individual patient, but, generally, between 0.1 mg and 100 mg inclusive are administered per day to an adult in any pharmaceutically acceptable formulation.
  • E4orf4 or PP2A biological activity may be administered within a pharmaceutically-acceptable diluent, carrier, or excipient, in unit dosage form.
  • Conventional pharmaceutical practice may be employed to provide suitable formulations or compositions to administer activating PP2A antibodies or compounds that mimic E4orf4 biological activity or modulate or mimic PP2A biological activity to patients suffering from a cell proliferation disease. Administration may begin before the patient is symptomatic. Methods well known in the art for making formulations are found, for example, in Remington: The Science and Practice of Pharmacy (supra).
  • Formulations for parenteral administration may, for example, contain excipients, sterile water, or saline, polyalkylene glycols such as polyethylene glycol, oils of vegetable origin, or hydrogenated napthalenes. Biocompatible. biodegradable lactide polymer, lactide/glycolide copolymer, or polyoxyethylene-polyoxypropylene copolymers may be used to control the release of the compounds.
  • Other potentially useful parenteral delivery systems for compounds include ethylene-vinyl acetate copolymer particles, osmotic pumps, implantable infusion systems, and liposomes.
  • Formulations for inhalation may contain excipients, for example, lactose, or may be aqueous solutions containing, for example, polyoxyethylene-9-lauryl ether, glycocholate and deoxycholate, or may be oily solutions for administration in the form of nasal drops, or as a gel.
  • excipients for example, lactose
  • aqueous solutions containing, for example, polyoxyethylene-9-lauryl ether, glycocholate and deoxycholate
  • glycocholate and deoxycholate may be oily solutions for administration in the form of nasal drops, or as a gel.
  • Ad2 adenovirus The complete genome of Ad2 adenovirus is found at GenBank locus ADRCG (NID No. g209811).
  • the Ad2 E4orf4 protein was tagged with a hemagglutinin (HA) tag, such that the expressed protein could be recognized with a commercially available anti-HA tag antibody.
  • HA hemagglutinin
  • E4orf4 is known to associate with the B subunit of PP2A (PP2A). While there are a number of B subunits of PP2A, in three separate families, E4orf4 only seems to interact with the B ⁇ subunit. A schematic representation of the interaction of E4orf4 with PP2A is shown in Fig. 4A.
  • E4orf4 immunoprecipitations with anti-HA tag antibody were performed, followed by an in vitro phosphatase assay of PP2A activity using a commercially available synthetic phospho-peptide containing a generic PP2A consensus site. Phosphate release was determined spectrophotometrically using malacite green. The same samples were then separated by SDS-PAGE, and blotted for the B ⁇ subunit of PP2A with commercially available anti-Flag antibody (Sigma, St. Louis, MO) to assess binding. In parallel. Western blotting analysis using anti-Flag antibody was performed on whole cell extracts to verify expression of the E4orf4 mutants and the PP2A B ⁇ subunit.
  • Fig. 4C Shown in Fig. 4C are the results from the phosphatase assay.
  • the majority of the E4orf4 mutants were associated with a phosphatase activity that was roughly equivalent to wild-type E4orf4 (HAorf4). Strikingly, there were a number of mutants that were highly defective in immunoprecipitating active phosphatase.
  • FIG. 5 is a schematic diagram showing the summary of the mutational analysis of E4orf4 protein.
  • the mutations shown in black in Fig. 5 completely disrupted the ability of E4orf4 to bind to B ⁇ . As expected, these mutants also failed to bring phosphatase activity in E4orf4 immunoprecipitates.
  • the mutations shown in diagonally hatch bars had a reduced ability to bind B ⁇ , and showed a corresponding drop in phosphatase activity. In our experiments, binding to B ⁇ correlated exactly with phosphatase activity in our in vitro phosphatase assay.
  • a lung carcinoma H 1299
  • a bone fibrosarcoma HT1080
  • an osteosarcoma line Saos-2
  • All the susceptible lines were p53 mutant or negative, except the HeLa cells which contain p53.
  • the normal lung fibroblast line, Mrc-5 was resistant to killing by stable expression of E4orf4.
  • an inactive E4orf4 mutant was used (white bars outlined with black, Fig. 6).
  • Bax a pro-apoptotic member of the Bcl-2 family that induces cell death in the vast majority of cells, was used as a positive control for killing (stippled bar, Fig. 6).
  • E4orf4 To allow us to introduce E4orf4 into primary human lines, we next generated an adenovirus vector producing E4orf4 alone, with no other viral genes expressed, using standard cloning procedures known in the art of molecular biology (see, e.g., Ausubel et al., supra).
  • the E4orf4 protein produced by a cell expressing this vector is, thus, substantially purified, since it is not associated with any other adenovirus-encoded proteins.
  • inducible adenovirus vector system in which the E4orf4 expression level is tightly controllable by titrating the amount of inducer (doxycycline, a tetracycline analogue).
  • inducer doxycycline, a tetracycline analogue
  • low levels of E4orf4 were non-toxic in the H1299 lung carcinoma line (0, 1 or 10 ng/mL Dox); moderate levels were slightly toxic (50 or 100 ng/mL Dox); and high levels were much more toxic (250, 500, 1000 ng/mL Dox). This indicates that high levels of E4orf4 protein are critical for good apoptosis induction.
  • the construction of the inducible adenovirus vector system is outlined in Fig. 7.
  • the first virus contains an HA-tagged version of E4orf4 under the control of the tetracycline-inducible promoter.
  • the second virus contains the reverse tetracycline transactivator (rtTA), a transcription factor that binds and activates the tetracycline-responsive promoter in Ad5-TindHAorF4 when bound to tetracycline (or doxycycline).
  • rtTA reverse tetracycline transactivator
  • the inducible system operates in a wide variety of tumor and normal cells (Fig. 8; also see below).
  • E4orf4 protein expression was monitored by immunoblot in detergent extracts at different doxycycline concentrations (Fig. 9). Cells were harvested 21 hours after infection with the inducible adenovirus vector system expressing HA-tagged E4orf4. E4orf4 expression was monitored over a time course to determine when maximum expression occurred and how long expression lasted. The low expression at the 72 hour time-point is a reflection of the fact that most of the cells are dead at this point. Fig.
  • FIG. 10 shows the results of a growth inhibition assay in which sparsely plated HI 299 cells were infected with the inducible E4orf4 virus + the CMV rtTA virus, the CMVrfTA virus only (at double the concentration) as a control for non-specific viral toxicity, an E1B-19K minus virus (a mutant adenovirus which is very toxic in most humans cells due to virus replication in the absence of apoptosis inhibition), or mock infected (no virus used). These samples were then treated with varying concentrations of doxycycline (matching the amounts used for the immunoblot) and live cells were counted daily under the microscope using a haemocytometer.
  • Cells expressing rtTA showed little or no decrease in cell number, while there was a dramatic reduction in the number of cells expressing rtTA and E4orf4 (Fig. 10).
  • a large number of human tumor lines were assayed for their sensitivity to killing by E4orf4 (Fig. 11 and Table 1).
  • the same method for scoring cell growth used for Fig.10 was used for many of the cell lines (indicated by *).
  • the other group of cells showed poor E4orf4 expression with the tetracycline-inducible system, and displayed greater viability, so they were further analyzed by colony assay.
  • plasmids expressing E4orf4 routinely exhibit 10-20% of the cells found in comparison to a control plasmid lacking E4orf4.
  • E4orf4 Five cell lines were not killed by tet-induced E4orf4 expression: U-87 MG glioblastoma; MDA-MB-231 epithelial breast adenocarcinoma; SK-OV-3 ovarian adenocarcinoma; 5637 epithelial bladder carcinoma; and NCI-H460 lung large cell carcinoma. Expression of E4orf4 in these cell lines was lower in these cell lines than that seen in H1299 cells. Thus, the inability of E4orf4 to kill these five cell lines may reflect inadequate E4orf4 protein levels. If these cell lines are resistant to E4orf4, they serve as control cell lines, for example, for screening for mimetics of E4orf4.
  • E4orf4 showed some specificity in killing tumor lines (both p53 plus and minus) while normal line was quite resistant. From these experiments, it is clear that E4orf4, recombinantly produced or substantially purified, may be used as a therapeutic agent to induce cell death in tumorigenic cells, while not adversely affecting normal cells.
  • E4orf4 proteins, mutants or analogs thereof, or nucleic acids encoding these proteins, having E4orf4 cell death-inducing activity may be administered according to standard methods with a pharmaceutically acceptable carrier, such as physiological saline or in formulations, such as those described in, for example, in Remington: The Science and Practice of Pharmacy, ( 19th ed.) ed. A.R. Gennaro AR., 1995, Mack Publishing Company, Easton, PA.
  • a pharmaceutically acceptable carrier such as physiological saline or in formulations, such as those described in, for example, in Remington: The Science and Practice of Pharmacy, ( 19th ed.) ed. A.R. Gennaro AR., 1995, Mack Publishing Company, Easton, PA.
  • Example 4 E4orf4 expression in S. cerevisiae phenocopies PP2A B subunit deletion mutants
  • HA-tagged E4orf4 cDNA was subcloned into the episomal yeast vector, pYES2, under the control of the GAL1 promoter.
  • the GAL1 promoter is repressed in the presence of glucose and induced in galactose, thus allowing differential expression of E4orf4 based on the carbon source contained in the growth medium.
  • E4orf4 expression had any effects on colony growth
  • spotting assays were performed comparing empty pYes2 vector, E4orf4, E311.6K, and Bax (Fig. 13A).
  • E311.6K is another adenovirus protein believed to be involved in viral induced cell death
  • Bax is a cellular pro-apoptotic protein which has previously been shown to be lethal in yeast.
  • Fig. 13B shows that all proteins were expressed at high levels. It was found that E4orf4 expression significantly delayed colony growth compared to the vector control. The E311.6K protein had some minor effect on growth. As demonstrated in previous studies, Bax expression resulted in a dramatic cessation of colony growth.
  • E4orf4 expressed in the SEY6210 diploid strain or EGY48 and BY4742 haploid yeast strains also yielded similar slow growth effects.
  • a trypan blue viability assay was done as a time course comparing cells expressing E4orf4 and vector alone. Cells were cultured in glucose, transferred to glycerol, and approximately equal numbers of cells were then resuspended in either galactose- or glucose-based medium. Cells expressing E4orf4 were almost all viable at all time points tested from 0 to 108 hours post-induction (Figs. 14A and 14B).
  • E4orf4-expressing cells displayed an abnormal elongated morphology (compare Figs. 15A and 15B) highly similar to the morphology observed in cdc55 strains at low temperatures (Fig. 15C).
  • Cdc55 shares 47% identity and 61% similarity with the human B ⁇ subunit.
  • This common morphological phenotype indicated that E4orf4 may be targeting Cdc55, the yeast homolog of the mammalian B ⁇ subunit, providing a molecular link between E4orf4's function in mammalian cells and yeast.
  • E4orf4 mediates its effects in yeast through the Cdc55 subunit and that the observed phenotype is not simply due to the overexpression of an exogenous protein.
  • E4orf4 mediates its effects in yeast through the Cdc55 subunit and that the observed phenotype is not simply due to the overexpression of an exogenous protein.
  • the expression of E4orf4 is much greater in the cdc55 deletion strain than in wild type cells (as shown in Fig. 16B). This is consistent with the observed E4orf4-induced toxicity in wild-type cells in which Cdc55 is intact, as it is conceivable that these cells would attempt to downregulate E4orf4 expression.
  • E4orf4 expression is much greater and the toxicity to yeast is dramatically decreased due to the absence of its cellular target.
  • E4orf4 and Cdc55 were confirmed biochemically with co-immunoprecipitation experiments (Figs. 17A- 17F).
  • Cells containing a CDC55 disruption were co-transformed with HA-tagged E4orf4 and Flag-tagged Cdc55 or the appropriate controls.
  • Whole cell extracts were prepared 24 hours post-galactose induction and incubated with either anti-HA or anti-Flag antibodies.
  • E4orf4 and Cdc55 co-immunoprecipitate, as shown in the immonoblots presented in Figs. 17B and 17D.
  • E4orf4-PP2A complex To further characterize the E4orf4-PP2A complex in yeast, cells containing E4orf4 plasmid were transformed with either Flag-tagged PPH2I or PPH22, which encode the PP2A catalytic subunits in S. cerevisiae (Figs. 18A-18I). Immunoprecipitation with HA antibody followed by western blotting with anti-Flag revealed that both Pph21 and Pph22 can be immunoprecipitated with E4orf4 (Fig. 18B). The reciprocal experiment, immunoprecipitating with Flag-antibody and blotting against the HA epitope, was also done to confirm this interaction (Fig. 18D).
  • E4orf4 alanine point mutants previously characterized in human cell lines based on their ability to bind B ⁇ , had an analogous phenotype in yeast.
  • R81 F84 does not bind B ⁇ and does not kill tumor cells.
  • K88 binds B ⁇ , but has no effect in cells.
  • Figs. 19A-19C wild type haploid yeast for colony growth, morphology, and Cdc55 binding.
  • Figs. 19B all mutants were stably expressed.
  • the spotting assay results show that S I 06 has a similar effect on colony growth as did wild-type
  • both K88 and R81/F84 had an intermediate effect on growth (Fig. 19A).
  • Cells from the plates were collected and examined for cell morphology.
  • Cells expressing the R81/F84 mutants appeared to have normal yeast mo ⁇ hology, resembling those containing vector alone.
  • Cells expressing the K88 mutant displayed largely normal mo ⁇ hology, although a few cells ( ⁇ 1%) did have an elongated cell mo ⁇ hology.
  • E4orf4 can associate with all four members of the B class regulatory subunits, but interaction with the B' or B" classes have not been detected.
  • the only other B regulatory subunit known to exist in budding yeast is Rtsl, which has homology to the B' class.
  • SUBST ⁇ UTE SHEET (RULE 26) type E4orf4 and E4orf4 mutants in an rtsl strain (Figs. 20A and 20B).
  • Haploid wild type yeast or yeast containing an RTSI deletion were transformed with the indicated plasmids and spotting assays were performed (Fig. 20A).
  • Fig. 20B shows that all proteins were expressed in the deletion strain. While the slow growth effect of wild type E4orf4 was essentially abrogated in the cdc55 strain, the growth delay was maintained in the rtsl strain. The E4orf4 mutants also displayed the intermediate growth delay in the rtsl strain.
  • Cdc55 subunit (B) is required by E4orf4 to elicit an effect in yeast while the Rtsl subunit is dispensable for E4orf4 function in yeast.
  • S. cerevisiae can serve as a useful organism for performing screens to identify E4orf4 analogs or mimetics that modulate PP2A biological activity.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Cette invention concerne l'aptitude de la protéine adénovirale E4orf4 à provoquer la mort de cellules néoplasiques, mais pas de cellules non néoplasiques. Cette découverte ouvre la voie à la mise au point de réactifs et de composés thérapeutiques anti-néoplasiques. De plus, l'invention concerne des méthodes de criblages d'analogues E4orf4 présentant des propriétés anti-néoplasiques.
EP00945500A 1999-07-12 2000-07-11 Polypeptides, modulateurs et mimetiques e4orf4 et pp2a permettant d'induire une mort cellulaire selective Withdrawn EP1196773A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US35160299A 1999-07-12 1999-07-12
US351602 1999-07-12
PCT/CA2000/000817 WO2001004629A1 (fr) 1999-07-12 2000-07-11 Polypeptides, modulateurs et mimetiques e4orf4 et pp2a permettant d'induire une mort cellulaire selective

Publications (1)

Publication Number Publication Date
EP1196773A1 true EP1196773A1 (fr) 2002-04-17

Family

ID=23381575

Family Applications (1)

Application Number Title Priority Date Filing Date
EP00945500A Withdrawn EP1196773A1 (fr) 1999-07-12 2000-07-11 Polypeptides, modulateurs et mimetiques e4orf4 et pp2a permettant d'induire une mort cellulaire selective

Country Status (4)

Country Link
EP (1) EP1196773A1 (fr)
AU (1) AU5959200A (fr)
CA (1) CA2377228A1 (fr)
WO (1) WO2001004629A1 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2827866B1 (fr) * 2001-07-27 2004-12-10 Pasteur Institut Peptides synthetiques ou naturels liant la proteine phosphatase 2a, methode d'identification et utilisations
CA2408207A1 (fr) 2002-10-16 2004-04-16 Institut Pasteur Peptides liant la proteine phosphatase 2a et polynucleotides les codant

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5695944A (en) * 1995-05-05 1997-12-09 Thomas Jefferson University Modulation of bcl-2 phosphorylation
EP0889971B1 (fr) * 1996-03-29 2002-05-29 Novartis AG Modulateur de la phosphatase
JP2000515504A (ja) * 1996-07-05 2000-11-21 フィリップ イー． ブラントン 細胞死を誘導するアデノウイルスｅ４蛋白質
EP0874052A3 (fr) * 1997-04-22 1999-02-24 BIOPHARM GESELLSCHAFT ZUR BIOTECHNOLOGISCHEN ENTWICKLUNG VON PHARMAKA mbH Acide nucléique codant pour une phosphatase de protéine humaine

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO0104629A1 *

Also Published As

Publication number Publication date
AU5959200A (en) 2001-01-30
CA2377228A1 (fr) 2001-01-18
WO2001004629A9 (fr) 2002-08-29
WO2001004629A1 (fr) 2001-01-18

Similar Documents

Publication Publication Date Title
Benkirane et al. Oncogenic potential of TAR RNA binding protein TRBP and its regulatory interaction with RNA-dependent protein kinase PKR
Cordle et al. Lipopolysaccharide induces phosphorylation of MAD3 and activation of c-Rel and related NF-kappa B proteins in human monocytic THP-1 cells
Cheng et al. Peptide antibodies to the human c‐fyn gene product demonstrate pp59c‐fyn is capable of complex formation with the middle‐T antigen of polyomavirus.
US7902165B2 (en) Use of AIM3 acting as a tumor suppressor
Yang et al. DNA Damage–Induced Protein 14-3-3 σ Inhibits Protein Kinase B/Akt Activation and Suppresses Akt-Activated Cancer
Grönholm et al. Homotypic and heterotypic interaction of the neurofibromatosis 2 tumor suppressor protein merlin and the ERM protein ezrin
Zhang et al. Role of Toll-like receptor signaling in the apoptotic response of macrophages to Yersinia infection
JP4418103B2 (ja) 新規なヒトチェックポイントキナーゼ、ｈＣＤＳ１、組成物および方法
JP2008505307A (ja) ＨＡＵＳＰ−Ｍｄｍ２相互作用及びその使用
Zhao et al. Myeloid neddylation targets IRF7 and promotes host innate immunity against RNA viruses
US5972674A (en) Stimulus-inducible protein kinase complex and methods of use therefor
US6534056B1 (en) Therapeutic and diagnostic uses of protein tyrosine phosphatase TC-PTP
EP0889971B1 (fr) Modulateur de la phosphatase
Miyazaki et al. In vitro and in vivo suppression of osteoclast function by adenovirus vector–induced csk gene
US20100310508A1 (en) METHODS OF TREATMENT INVOLVING p21/CIP1
EP1196773A1 (fr) Polypeptides, modulateurs et mimetiques e4orf4 et pp2a permettant d'induire une mort cellulaire selective
WO2001004296A1 (fr) Polypeptides rbp1 et leurs utilisations
US7629308B2 (en) Methods relating to muscle selective calcineurin interacting protein (MCIP)
WO1995021923A1 (fr) Production et utilisation de map-kinases phosphatases et acides nucleiques de codage prevus a cet effet
JP2003531581A (ja) 黒色腫分化関連遺伝子−５およびプロモーターならびにこれらの使用
Cheng et al. Stoichiometry of cellular and viral components in the polyomavirus middle-T antigen-tyrosine kinase complex
WO2019024518A1 (fr) Médicament pour le traitement d'une maladie impliquant la protéine chimioattractive des monocytes de type 1 (mcp-1) par ajustement de la phosphorylation de yb-1
US6960430B2 (en) Screening methods for compounds useful in the regulation of cell proliferation
US20040048821A1 (en) Enhancement of drug cytotoxicity in tumor cells containing mutant Rb gene
WO2002042489A9 (fr) Methodes faisant intervenir la proteine tyrosine phosphatase de lymphocyte t

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20020206

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

RIN1 Information on inventor provided before grant (corrected)

Inventor name: LEE, JOSEPH, M.

Inventor name: SHAHINIAN, S., SERGE

Inventor name: MARCELLUS, RICHARD, C.

Inventor name: BRANTON, PHILIP, E.

Inventor name: ROOPCHAND, DIANA, E.

Inventor name: BUSSEY, A., HOWARD

Inventor name: SHORE, GORDON, C.

17Q First examination report despatched

Effective date: 20030909

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20040120